MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence

MedBright AI Announces Limmi Disease Insights Platform Being Used in University Hospital Setting to Improve Detection of Kidney Stone Disease Recurrence
Article Date
February 22, 2024
Press Releases

VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- MedBright AI Investments Inc. (the “Company” or “MedBright”) (CSE:MBAI, OTCQB:MBAIF) is pleased to announce that the Limmi Disease Insights Platform is now being used in hospitals with an initial focus on kidney stone disease recurrence. Limmi is a key investment in Medbright’s AI Healthcare portfolio.

UC San Diego Health is the first site that is utilizing Limmi’s Disease Insights Platform in a hospital setting.

"We envision a future where we – through the use of AI - can reveal the hidden patterns of data, in order to assist in minimizing the recurrence of kidney stone disease and ultimately provide better care to patients," states Trevor Vieweg.

Limmi's Disease Insights Platform has been meticulously designed to address the common challenges researchers face when dealing with large sets of data, particularly complex health data. Limmi's Disease Insights Platform offers a suite of tools including advanced AI modeling, comprehensive data integration from all common healthcare data types, collaborative tools for researchers, and real-time analysis of continuous learning from real world data.

"We know that recurring kidney stones affect approximately 50% of patients—but we don't have a personalized risk predictor for individual patients. We have fortunately collected years of high quality kidney stone patient data to apply to Artificial Intelligence (AI). The goal is to create a high fidelity AI model that will predict an individual's risk of kidney stone recurrence", states Dr. Roger Sur, Professor of Urology at UC San Diego School of Medicine and Director, Comprehensive Kidney Stone Center, and urologist at UC San Diego Health.

In the near future, Limmi hopes to use AI with physicians to predict other diseases such as a person's risk of cancer, eventually growing into other areas of healthcare management in the future.

About MedBright AI Investments Inc.

MedBright AI is a capital allocator focused on investing in healthcare technology companies. The team at MedBright prides themselves on unparalleled access to opportunities, as well as structuring unique and advantageous investments. MedBright's mission is to construct a portfolio of synergistic investments to generate superior returns for shareholders. MedBright will focus on significant near-term and midterm high-quality opportunities with strong return potentials while maintaining commitment to governance. Click here to view the MedBright AI corporate video.

MedBright AI Investments Inc.
Trevor Vieweg, Chief Executive Officer

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation, the intended use of Limmi’s Disease Insights Platform to aid in predicting future medical information such as kidney stone recurrence and cancer risk, and the Company’s plans to generate returns for its shareholders through its portfolio of investments, are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should” or “would” occur.

Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that Limmi’s Disease Insights Platform will be able to predict future medical information such as kidney stone recurrence and cancer risk, and that the Company will be able to generate returns for its shareholders. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that the use of Limmi’s Disease Insights Platform will not be able to predict future medical information such as kidney stone recurrence and cancer risk, and the risk that the Company’s portfolio of investments will not generate returns for shareholders.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.